Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes-Reference-Cited by-同舟云学术

Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes

Published:2013-09-16 Issue:6 Volume:55 Page:1300-1303
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Xicoy Blanca,Jiménez María-José,García Olga,Bargay Joan,Martínez-Robles Violeta,Brunet Salut,Arilla María-Jesús,Pérez de Oteyza Jaime,Andreu Rafael,Casaño Francisco-Javier,Cervero Carlos-Javier,Bailén Alicia,Díez María,González Bernardo,Vicente Ana-Isabel,Pedro Carme,Bernal Teresa,Luño Elisa,Cedena María-Teresa,Palomera Luis,Simiele Adriana,Calvo José-Manuel,Marco Víctor,Gómez Eduardo,Gómez Marta,Gallardo David,Muñoz Juan,de Paz Raquel,Grau Javier,Ribera Josep-Maria,Benlloch Luis-Enrique,Sanz Guillermo

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.834532

Reference17 articles.

1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

2. Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes

3. Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

4. Proposals for the classification of the myelodysplastic syndromes

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperleukocytosis and leukostasis in acute and chronic leukemias;Leukemia & Lymphoma;2022-03-31

2. Polyurethane foam dressings ameliorating local adverse effects of azacitidine: a randomized controlled trial;Leukemia & Lymphoma;2021-11-25

3. Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine;Annals of Hematology;2020-01-28

4. A multicenter report on the natural history of myelodysplastic syndromes in very old patients (aged over 85 years);Leukemia & Lymphoma;2019-01-11

5. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes;BMC Hematology;2018-02-01